D Butov1, C Lange2, J Heyckendorf3, I Kalmykova4, T Butova5, N Borovok4, M Novokhatskaya4, D Chesov6. 1. Kharkiv National Medical University, Kharkiv, Ukraine. 2. Research Center Borstel, Clinical Infectious Diseases, Borstel, Germany, German Center for Infection Research (DZIF) Clinical Tuberculosis Unit, Borstel, Germany, Department of Internal Medicine, Karolinska Institute, Stockholm, Sweden. 3. Research Center Borstel, Clinical Infectious Diseases, Borstel, Germany, German Center for Infection Research (DZIF) Clinical Tuberculosis Unit, Borstel, Germany. 4. Kharkiv Regional Anti-Tuberculosis Dispensary No 1, Kharkiv. 5. VN Karazin Kharkiv National University, Kharkiv, Ukraine. 6. Research Center Borstel, Clinical Infectious Diseases, Borstel, Germany, German Center for Infection Research (DZIF) Clinical Tuberculosis Unit, Borstel, Germany, Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Moldova.
Abstract
OBJECTIVE: To document the level of drug resistance in MDR-TB patients and to characterize management capacities for their medical care and MDR-TB treatment outcomes in the Kharkiv region of Ukraine. This area has one of the highest frequencies of MDR-TB worldwide. METHODS: A retrospective observational cohort study was performed on registry data from the regional anti-TB dispensary in Kharkiv. All microbiologically confirmed MDR-TB patients registered in 2014 were included. Diagnostic, treatment and post-treatment follow-up data were analysed. RESULTS: Of 169 patients with MDR-TB, 55.0% had pre-extensively drug-resistant (pre-XDR) or XDR resistant patterns. Rapid molecular diagnosis by GeneXpert and liquid M. tuberculosis cultures were only available for 66.9% and 56.8% of patients, respectively. Phenotypic drug-susceptibility testing (DST) for high priority TB drugs (bedaquiline, linezolid, clofazimine) were not available. DST for later generation fluroquinolones was available only in 53.2% of patients. 50.9% of patients had less than 4 drugs in the treatment regimen proven to be effective by DST. More than 23.1% of patients with MDR-TB failed their treatment and only 45.0% achieved a cure. CONCLUSION: The high prevalence of MDR-TB and poor MDR-TB treatment outcomes in the Kharkiv region, is associated with substantial shortages in rapid molecular and phenotypic DST, a lack of high priority MDR-TB drugs, poor treatment monitoring and follow-up capacities.
OBJECTIVE: To document the level of drug resistance in MDR-TBpatients and to characterize management capacities for their medical care and MDR-TB treatment outcomes in the Kharkiv region of Ukraine. This area has one of the highest frequencies of MDR-TB worldwide. METHODS: A retrospective observational cohort study was performed on registry data from the regional anti-TB dispensary in Kharkiv. All microbiologically confirmed MDR-TBpatients registered in 2014 were included. Diagnostic, treatment and post-treatment follow-up data were analysed. RESULTS: Of 169 patients with MDR-TB, 55.0% had pre-extensively drug-resistant (pre-XDR) or XDR resistant patterns. Rapid molecular diagnosis by GeneXpert and liquid M. tuberculosis cultures were only available for 66.9% and 56.8% of patients, respectively. Phenotypic drug-susceptibility testing (DST) for high priority TB drugs (bedaquiline, linezolid, clofazimine) were not available. DST for later generation fluroquinolones was available only in 53.2% of patients. 50.9% of patients had less than 4 drugs in the treatment regimen proven to be effective by DST. More than 23.1% of patients with MDR-TB failed their treatment and only 45.0% achieved a cure. CONCLUSION: The high prevalence of MDR-TB and poor MDR-TB treatment outcomes in the Kharkiv region, is associated with substantial shortages in rapid molecular and phenotypic DST, a lack of high priority MDR-TB drugs, poor treatment monitoring and follow-up capacities.
Authors: Hans-Peter Grobbel; Matthias Merker; Niklas Köhler; Sönke Andres; Harald Hoffmann; Jan Heyckendorf; Maja Reimann; Ivan Barilar; Viola Dreyer; Doris Hillemann; Barbara Kalsdorf; Thomas A Kohl; Patricia Sanchez Carballo; Dagmar Schaub; Katharina Todt; Christian Utpatel; Florian P Maurer; Christoph Lange; Stefan Niemann Journal: Clin Infect Dis Date: 2021-10-05 Impact factor: 9.079